The Central Epidemic Command Center (CECC) is planning to initiate a public-private partnership to develop antibody treatments against COVID-19, the National Health Research Institutes (NHRI) said on Friday.
Antibody treatments, to be administered to people infected with COVID-19 and healthy individuals to provide short-term immunity, are a vital stopgap treatment until vaccines become widely available, NHRI vice president Sytwu Huey-kang (司徒惠康) said.
The institute, Academia Sinica, National Taiwan University Hospital and Chang Gung Medical Foundation last year began developing COVID-19 antibody treatments, but their efforts have largely been uncoordinated, Sytwu said.
To expedite the process, the CECC’s research division is planning to set up a platform to increase cooperation between the institutions, and promote the development of antibody treatments by local drug manufacturers, he said.
The treatments are based on the injection of antibodies that attach themselves to a specific virus, which prevents the virus from attacking cells, Sytwu said, adding that the treatment aims to limit the progression of an infection.
Many antibody treatments, such as the drug administered to US President Donald Trump last year, use a cocktail of multiple antibodies that target different parts of a virus, increasing their overall efficacy, he said.
Because antibody treatments can provide up to two months of immunity to a certain virus, they could also be administered to healthy people who are at risk of infection, for example those who need to travel abroad, before a COVID-19 vaccination is widely available, Sytwu said.
The treatments are also extremely safe and could be combined with a vaccination to offer better protection to people with a history of allergic reactions to vaccinations, he said.
OVERHAUL NEEDED: The government should improve its agricultural processing capabilities and expand to new markets to limit its reliance on China, an expert said China’s ban on Taiwanese pineapples was “unsurprising,” and Taiwan should have years ago altered its produce export strategies and target customers, experts said. China on Friday abruptly suspended imports of pineapples from Taiwan, saying that it had on multiple occasions discovered “harmful biological entities” on the fruit. Calling it an “unfriendly” move, the Council of Agriculture (COA) said that 99.79 percent of the pineapples sent to China since last year have met China’s import standards. Chiao Chun (焦鈞), the author of Fruits and Politics — A Recollection of Cross-strait Agricultural Interaction Over the Past Decade (水果政治學：兩岸農業交流十年回顧與展望), said that China’s announcement is clearly targeting
The Council of Agriculture yesterday signed a Taiwan-Australia Agricultural Cooperation Implementation clause to open a new export market for the nation’s pineapple crop. The clause is an addition to existing cooperation measures, it said. China on Friday last week abruptly announced that it would suspend pineapple imports from Taiwan starting on Monday, on grounds that it had on multiple occasions discovered “harmful organisms” in shipments of the fruit. The public and private sectors have since joined hands to purchase the local fruit to help the nation’s pineapple farmers. Canberra has requested that all pineapples for export to Australia have their crown buds removed,
DECADES OF INFLUENCE: Over the past 20 years, China has made inroads with Aborigines, funding political campaigns and trips, a legislator said Lawmakers have called on the National Security Bureau to investigate claims of pervasive Chinese influence among Aboriginal communities. Legislators pointed to a surge in communist propaganda and Chinese-funded projects over the past few years, which they say are aimed at infiltrating and buying political influence among Aboriginal communities. “China has for decades carried out wide-ranging ‘united front’ tactics and propaganda campaigns targeting Aborigines,” said Democratic Progressive Party (DPP) Legislator Chen Ying (陳瑩), a member of the Puyuma community in Taitung County. “Now, they are influencing elections for local councilors and village chiefs, offering money for candidates to mount their campaigns, and to
Shanghai Fosun Pharmaceutical Group might have lost its right to distribute the Pfizer-BioNTech vaccine for COVID-19 and the ability to fulfill a contract in Taiwan, civic groups Taiwan Citizen Front and the Economic Democracy Union said yesterday. In a radio interview on Feb. 17, Minister of Health and Welfare Chen Shih-chung (陳時中), head of the Central Epidemic Command Center, said that last year, Taiwan was close to signing a contract to buy doses of the Pfizer-BioNTech vaccine, but that the deal was halted at the last moment, with some speculating that Chinese interference was to blame. On Monday last week, the center